(Q36780141)

16 August 2017

1 reference

title

Pulmonary vaccine delivery (English)

1 reference

16 August 2017

Dongmei Lu

1

1 reference

16 August 2017

Anthony J Hickey

series ordinal

2

1 reference

16 August 2017

publication date

1 April 2007

1 reference

Expert Review of Vaccines

16 August 2017

published in

1 reference

16 August 2017

volume

6

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

213-226

1 reference

Anatomical features of anti-viral immunity in the respiratory tract

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Humoral immune response patterns of human mucosae: induction and relation to bacterial respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

The mucosal immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Mucosa-associated lymphoid tissues as sites for uptake, carriage and excretion of tubercle bacilli and other pathogenic mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Vaccines for mucosal immunity to combat emerging infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

The common mucosal immune system and current strategies for induction of immune responses in external secretions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Homing of naive, memory and effector lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Human airway epithelia express a beta-defensin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Pulmonary DNA vaccination: concepts, possibilities and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Bronchus- and nasal-associated lymphoid tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Aerogenic BCG vaccination against tuberculosis in animal and human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Human live anthrax vaccine in the former USSR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Anthrax post-vaccinal cell-mediated immunity in humans: kinetics pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Alternative routes of measles immunization: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

How many infective viral particles are necessary for successful mass measles immunization by aerosol?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

A powder formulation of measles vaccine for aerosol delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Local and systemic immune responses to intratracheal instillation of antigen and DNA vaccines in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Modulating airway defenses against microbes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Estimating the particle size characteristics of therapeutic aerosols

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Airborne immunization against tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Delivery of DNA-cationic liposome complexes by small-particle aerosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Active and intelligent inhaler device development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Dry powder inhalation as a potential delivery method for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Vaccine adjuvant technology: from mechanistic concepts to practical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

RETRACTED: Polyethyleneimine-based gene therapy by inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A/WSN virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Liposomal dry powders as aerosols for pulmonary delivery of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Nebulization of liposomes. III. The effects of operating conditions and local environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Receptor-mediated targeting of spray-dried lipid particles coformulated with immunoglobulin and loaded with a prototype vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Targeting dendritic cells with biomaterials: developing the next generation of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Liposomal delivery of antigen to human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Gene-based vaccines and immunotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Vaccination with a Sindbis virus-based DNA vaccine expressing antigen 85B induces protective immunity against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

PEI - a potent, but not harmless, mucosal immuno-stimulator of mixed T-helper cell response and FasL-mediated cell death in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Alternative sugars as potential carriers for dry powder inhalations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Protein inhalation powders: spray drying vs spray freeze drying

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

PLGA microcapsules with novel dimpled surfaces for pulmonary delivery of DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

21 January 2018

Vaccination and allergy

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Current status of DNA vaccines and their route of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.213

21 January 2018

Identifiers

DOI

10.1586/14760584.6.2.213

1 reference

16 August 2017

1 reference